The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus
Open accessAbstract
Systemic autoimmune disease in humans and mice is characterized by loss of immunologic tolerance to a restricted set of self-nuclear antigens. Autoantigens, such as double-stranded (ds) DNA and the RNA-containing Smith antigen (Sm), may be selectively targeted in systemic lupus erythematosus because of their ability to activate a putative common receptor. Toll-like receptor 9 (TLR9), a receptor for CpG DNA, has been implicated in the activation of autoreactive B cells in vitro, but its role in promoting autoantibody production and disease in vivo has not been determined. We show that in TLR9-deficient lupus-prone mice, the generation of anti-dsDNA and antichromatin autoantibodies is specifically inhibited. Other autoantibodies, such as anti-Sm, are maintained and even increased in TLR9-deficient mice. In contrast, ablation of TLR3, a receptor for dsRNA, did not inhibit the formation of autoantibodies to either RNA- or DNA-containing antigens. Surprisingly, we found that despite the lack of anti-dsDNA autoantibodies in TLR9-deficient mice, there was no effect on the development of clinical autoimmune disease or nephritis. These results demonstrate a specific requirement for TLR9 in autoantibody formation in vivo and indicate a critical role for innate immune activation in autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“TLR9, a receptor for hypomethylated CpG DNA motifs (9), is expressed by B cells in humans (10) and mice (9) and has been implicated in the breakdown of immunologic tolerance to self-nucleic acids in SLE.”
BackgroundSelf-citationTakeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Self-citationRecognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251 · cited 1×
“For example, the ability of TLR stimulation to promote homeostatic repair processes without the induction of an inflammatory or adaptive immune response was recently demonstrated in a model of induced intestinal injury (65).”
BackgroundToll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Self-citationInnate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., et al. (2003) · Science · doi:10.1126/science.1087262 · Cited by 3,235
Self-citationDevelopment of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S., Chamilos, G., Sebasigari, R., Riccieri, V., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001180 · Cited by 1,303
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
New insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
Self-citationType I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Banchereau, J., & Pascual, V. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.010 · Cited by 963
Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer
Karin, M., Lawrence, T., & Nizet, V. (2006) · Cell · doi:10.1016/j.cell.2006.02.016 · Cited by 942
Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., Christensen, S. R., Shlomchik, M. J., Viglianti, G. A., Rifkin, I. R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050630 · Cited by 812
Self-citationA cell biological view of Toll-like receptor function: regulation through compartmentalization
Barton, G. M., & Kagan, J. C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2587 · Cited by 709
Deane, J. A., Pisitkun, P., Barrett, R. S., Feigenbaum, L., Town, T., Ward, J. M., Flavell, R. A., & Bolland, S. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.009 · Cited by 636
Self-citationGottenberg, J.-E., Cagnard, N., Lucchesi, C., Letourneur, F., Mistou, S., Lazure, T., Jacques, S., Ba, N., Ittah, M., Lepajolec, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510837103 · Cited by 611
Nucleic acid recognition by the innate immune system
Barbalat, R., Ewald, S. E., Mouchess, M. L., & Barton, G. M. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101340 · Cited by 577
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
Baccala, R., Hoebe, K., Kono, D. H., Beutler, B., & Theofilopoulos, A. N. (2007) · Nature Medicine · doi:10.1038/nm1590 · Cited by 473
Cancro, M. P. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-092419-031130 · Cited by 464
Innate immunity to Toxoplasma gondii infection
Yarovinsky, F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3598 · Cited by 462
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Interferons and viruses: an evolutionary arms race of molecular interactions
Hoffmann, H.-H., Schneider, W. M., & Rice, C. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.01.004 · Cited by 410
Marshak-Rothstein, A., & Rifkin, I. R. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104514 · Cited by 389
BAFF and MyD88 signals promote a lupuslike disease independent of T cells
Groom, J. R., Fletcher, C. A., Walters, S. N., Grey, S. T., Watt, S. V., Sweet, M. J., Smyth, M. J., Mackay, C. R., & Mackay, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062567 · Cited by 377
Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
Krieg, A. M., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 350
Nickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K., & Shlomchik, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902592 · Cited by 347
Self-citationEhlers, M., Fukuyama, H., McGaha, T. L., Aderem, A., & Ravetch, J. V. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052438 · Cited by 339
Integration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Toll-like receptor signalling in B cells during systemic lupus erythematosus
Fillatreau, S., Manfroi, B., & Dörner, T. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00544-4 · Cited by 322
Sites and Stages of Autoreactive B Cell Activation and Regulation
Shlomchik, M. J. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.004 · Cited by 312
Self-citationAltered B cell signalling in autoimmunity
Rawlings, D. J., Metzler, G., Wray-Dutra, M., & Jackson, S. W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.24 · Cited by 308
Watanabe, R., Ishiura, N., Nakashima, H., Kuwano, Y., Okochi, H., Tamaki, K., Sato, S., Tedder, T. F., & Fujimoto, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902385 · Cited by 308
Systemic lupus erythematosus: all roads lead to type I interferons
Pascual, V., Farkas, L., & Banchereau, J. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.014 · Cited by 285
Yokogawa, M., Takaishi, M., Nakajima, K., Kamijima, R., Fujimoto, C., Kataoka, S., Terada, Y., & Sano, S. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38298 · Cited by 284
Cyclical palmitoylation regulates TLR9 signalling and systemic autoimmunity in mice
Ni, H., Wang, Y., Yao, K., Wang, L., Huang, J., Xiao, Y., Chen, H., Liu, B., Yang, C. Y., & Zhao, J. (2024) · Nature Communications · doi:10.1038/s41467-023-43650-z · Cited by 281
TLR‐mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells
Barr, T. A., Brown, S., Ryan, G., Zhao, J., & Gray, D. (2007) · European Journal of Immunology · doi:10.1002/eji.200636483 · Cited by 281
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Chaturvedi, A., Dorward, D., & Pierce, S. K. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.019 · Cited by 272
Type I interferons: crucial participants in disease amplification in autoimmunity
Hall, J. C., & Rosen, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.237 · Cited by 265
Toll-like Receptor 7-Dependent Loss of B Cell Tolerance in Pathogenic Autoantibody Knockin Mice
Berland, R., Fernandez, L., Kari, E., Han, J.-H., Lomakin, I., Akira, S., Wortis, H. H., Kearney, J. F., Ucci, A. A., & Imanishi-Kari, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.014 · Cited by 256
Self-citationPharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis
Pisitkun, P., Ha, H.-L., Wang, H., Claudio, E., Tivy, C. C., Zhou, H., Mayadas, T. N., Illei, G. G., & Siebenlist, U. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.014 · Cited by 174
Lartigue, A., Courville, P., Auquit, I., François, A., Arnoult, C., Tron, F., Gilbert, D., & Musette, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1349 · Cited by 165
Liu, B., & Li, Z. (2008) · Blood · doi:10.1182/blood-2008-03-143107 · Cited by 129
Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9
Tursi, S. A., Lee, E. Y., Medeiros, N. J., Lee, M. H., Nicastro, L. K., Buttaro, B., Gallucci, S., Wilson, R. P., Wong, G. C. L., & Tükel, Ç. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006315 · Cited by 115
“Lupus-prone mice deficient in TLR9 do not develop anti-dsDNA autoantibodies, although other disease markers are increased [75, 76].”
BackgroundRegulation of autoreactive B cell responses to endogenous TLR ligands
Avalos, A. M., Busconi, L., & Marshak-Rothstein, A. (2010) · Autoimmunity · doi:10.3109/08916930903374618 · Cited by 114
“Although TLR3 deficiency does not appear to have an effect on immune activation or clinical disease in Fas-deficient mice [53], recent studies suggest that TLR3 can be activated by certain mammalian RNAs that form structures with regions of dsRNA [54].”
BackgroundRNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113
Shen, L., Tenzer, S., Storck, W., Hobernik, D., Raker, V. K., Fischer, K., Decker, S., Dzionek, A., Krauthäuser, S., Diken, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.049 · Cited by 74
Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis
Pandey, S. P., Bender, M. J., McPherson, A. C., Phelps, C. M., Sanchez, L. M., Rana, M., Hedden, L., Sangani, K. A., Chen, L., Shapira, J. H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.05.006 · Cited by 72
Metadata
- Authors
- Christensen, S. R., Kashgarian, M., Alexopoulou, L., Flavell, R. A., Akira, S., & Shlomchik, M. J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2005-07-18
- Volume
- 202
- Issue
- 2
- Pages
- 321-331
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2166626628
- Cited by
- 516
- References
- 63
- FWCI
- 26.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.